This molecular epidemiology proposal is to continue applying knowledge of pharmacogenomic implications of gene expression of individual drug metabolizing enzymes to assess their role as risk markers for bladder cancer. We propose to use measures of whole body activity for drug metabolizing enzymes using the Pittsburgh cocktail that comprises CYP1A2 (caffeine), CYP2C19 (S-mephenytoin), CYP2D6 (debrisoquine), CYP2E1 (chlorzoxazone) and CYP3A4 (dapsone), as well as mRNA concentrations for each of these CYP enzymes in leukocytes and genotypic identification of known polymorphisms of CYP metabolizing enzymes to include CYP2D6 and CYP2E1. We will assess acetylation using a phenotypic trait measure (dapsone), supplemented by genotyping as well as GSTMI, and GSSTI using genotyping. Our initial work has provided evidence that high activity for CYPD6, low activity of CYP3A4, mutant alleles for acetylation and the null genotype for GSTMI are risk factors for bladder cancer, but to different extent for various forms of this cancer. We have also shown that high CYP2D6 activity is associated with mutations of the retinoblastoma (Rb) gene and low activity of CYP3A4 is independently associated with p53 mutations. Furthermore, different groups of risk factors relate to different mutational spectra of p53. We now propose to extend these observations.
Our specific aim i s to test the hypothesis that bladder cancer is comprised of a heterogeneous group of diseases in which different groups of associated risk factors relate to disease states that not only vary in etiology, but also in histopathological expression and natural history of the disease. This hypothesis will be evaluated in a case-control study of over 200 patients with incidence presentation of bladder cancer and over 200 controls matched for age, gender and ethnicity, in which environmental and constitutive variables will be related to the disease process. This study will involve a protocol that incorporates an exposure questionnaire, the Pittsburgh cocktail and blood sampling for mRNA quantitation and DNA genotyping. The disease process will be evaluated by clinical assessment and staging, identification of mutations of p53 and Rb genes, blinded histopathological review with grading and following the natural history for the disease. Collectively, these molecular epidemiology studies will improve our understanding of pathogenic mechanisms involved in different forms of bladder cancer and will expand our understanding of the regulation of the gene products that are responsible for drug metabolism in humans.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA059834-08
Application #
6607421
Study Section
Epidemiology and Disease Control Subcommittee 2 (EDC)
Program Officer
Verma, Mukesh
Project Start
1994-07-01
Project End
2005-06-30
Budget Start
2003-07-01
Budget End
2004-06-30
Support Year
8
Fiscal Year
2003
Total Cost
$395,999
Indirect Cost
Name
University of Pittsburgh
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Gao, Weimin; Romkes, Marjorie; Zhong, Shilong et al. (2010) Genetic polymorphisms in the DNA repair genes XPD and XRCC1, p53 gene mutations and bladder cancer risk. Oncol Rep 24:257-62
Cecchetti, Alfred A; Parmanto, Bambang; Vecchio, Marcella L et al. (2009) Team building: electronic management-clinical translational research (eM-CTR) systems. Clin Transl Sci 2:449-55
Backer, Lorraine C; Lan, Qing; Blount, Benjamin C et al. (2008) Exogenous and endogenous determinants of blood trihalomethane levels after showering. Environ Health Perspect 116:57-63
Zgheib, N K; Frye, R F; Tracy, T S et al. (2007) Evaluation of flurbiprofen urinary ratios as in vivo indices for CYP2C9 activity. Br J Clin Pharmacol 63:477-87
Zgheib, Nathalie K; Frye, Reginald F; Tracy, Timothy S et al. (2006) Validation of incorporating flurbiprofen into the Pittsburgh cocktail. Clin Pharmacol Ther 80:257-63
Bebia, Zourab; Buch, Shama C; Wilson, John W et al. (2004) Bioequivalence revisited: influence of age and sex on CYP enzymes. Clin Pharmacol Ther 76:618-27
Carcillo, Joseph A; Adedoyin, Adedayo; Burckart, Gilbert J et al. (2003) Coordinated intrahepatic and extrahepatic regulation of cytochrome p4502D6 in healthy subjects and in patients after liver transplantation. Clin Pharmacol Ther 73:456-67
Nolin, Thomas D; Frye, Reginald F (2003) Stereoselective determination of the CYP2C19 probe drug mephenytoin in human urine by gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 783:265-71
Branch, R A; Adedoyin, A; Frye, R F et al. (2000) In vivo modulation of CYP enzymes by quinidine and rifampin. Clin Pharmacol Ther 68:401-11
Adedoyin, A; Stiff, D D; Smith, D C et al. (1998) All-trans-retinoic acid modulation of drug-metabolizing enzyme activities: investigation with selective metabolic drug probes. Cancer Chemother Pharmacol 41:133-9

Showing the most recent 10 out of 17 publications